AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23485514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoic acid (1200 mg/day)
Number of subjects: 52
Study 23485514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22432727 — intervention group
Group type: EXPERIMENTAL
Intervention: insuVida™ (hydrolyzed casein)
Number of subjects: 36
Study 22432727 — intervention group
Group type: EXPERIMENTAL
Intervention: insuVida™ plus added leucine
Number of subjects: 36
Study 22432727 — intervention group
Group type: EXPERIMENTAL
Intervention: unhydrolyzed casein
Number of subjects: 36
Study 22432727 — intervention group
Group type: COMPARATOR
Intervention: insuVida™, unhydrolyzed casein, and placebo
Number of subjects: 36
Study 18163196 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide (two 180 microg/kg boluses followed by infusion at 2.0 and 1.3 microg/kg/min for 24 and 48 h, respectively)
Number of subjects: 25
Study 18163196 — intervention group
Group type: COMPARATOR
Intervention: Control group (treated without GP IIb‐IIIa antagonists)
Number of subjects: 25
Study 17588545 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (125 mg)
Number of subjects: 0
Study 17588545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15765857 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 10
Study 15765857 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 10
Study 15765857 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (MS)
Number of subjects: 10
Study 15765857 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline (PRE)
Number of subjects: 10
Study 11159249 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of dextromethorphan given eight hourly
Number of subjects: 66
Study 11159249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9773893 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl-NaCitrate beverage (185 mEq x L(‐1) Na+, 283 mOsm x kg(‐1))
Number of subjects: 10
Study 9773893 — intervention group
Group type: EXPERIMENTAL
Intervention: NaCl-NaCitrate beverage (21.6 mEq x L(‐1) Na+, 365 mOsm x kg(‐1))
Number of subjects: 10
Study 9773893 — intervention group
Group type: EXPERIMENTAL
Intervention: Water at ALT
Number of subjects: 10
Study 9773893 — intervention group
Group type: EXPERIMENTAL
Intervention: Water on the ground
Number of subjects: 10
Study 8144825 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 41
Study 8144825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2843314 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg intravenously, followed by a continuous infusion of 10 mg/h)
Number of subjects: 10
Study 2843314 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 10
Study 2843314 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 10
Study 2843314 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone and Saline
Number of subjects: 10
Study 31629030 — intervention group
Group type: EXPERIMENTAL
Intervention: etch‐and‐rinse with 0.1% CuNp (ERcu)
Number of subjects: 36
Study 31629030 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐etch with 0.1% CuNp (SEcu)
Number of subjects: 36
Study 31629030 — intervention group
Group type: COMPARATOR
Intervention: etch‐and‐rinse without CuNp (ERct)
Number of subjects: 36
Study 31629030 — intervention group
Group type: COMPARATOR
Intervention: self‐etch without CuNp (SEct)
Number of subjects: 36
Study 28522759 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IB; 10 mg/kg)
Number of subjects: 7
Study 28522759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 7
Study 26226987 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose impact-loading (80 jumps per session)
Number of subjects: 42
Study 26226987 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose impact-loading (40 jumps per session)
Number of subjects: 42
Study 26226987 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 42
Study 23260857 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS with transfer on day 5 (AMA study)
Number of subjects: 274
Study 23260857 — intervention group
Group type: COMPARATOR
Intervention: Blastocyst transfer on day 5 (AMA study)
Number of subjects: 274
Study 23260857 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS with transfer on day 5 (RIF study)
Number of subjects: 274
Study 23260857 — intervention group
Group type: COMPARATOR
Intervention: Blastocyst transfer on day 5 (RIF study)
Number of subjects: 274
Study 21216518 — intervention group
Group type: EXPERIMENTAL
Intervention: LUAO+M
Number of subjects: 332
Study 21216518 — intervention group
Group type: COMPARATOR
Intervention: CISH
Number of subjects: 332
Study 18416075 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion and Chinese Tuina
Number of subjects: 92
Study 18416075 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture-moxibustion
Number of subjects: 92
Study 17172188 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60
Study 17172188 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 60
Study 14529447 — intervention group
Group type: EXPERIMENTAL
Intervention: Dartmouth-regimen combination chemotherapy
Number of subjects: 0
Study 14529447 — intervention group
Group type: COMPARATOR
Intervention: Single agent chemotherapy
Number of subjects: 0
Study 11120515 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise 3 to 5 times a week for the remainder of pregnancy
Number of subjects: 46
Study 11120515 — intervention group
Group type: COMPARATOR
Intervention: No exercise
Number of subjects: 46
Study 11120515 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-bearing exercise
Number of subjects: 46
Study 11248877 — intervention group
Group type: EXPERIMENTAL
Intervention: High alpha-linolenic formula (HLF)
Number of subjects: 63
Study 11248877 — intervention group
Group type: COMPARATOR
Intervention: Low alpha-linolenic formula (LLF)
Number of subjects: 63
Study 8325826 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management program
Number of subjects: 27
Study 8325826 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management program with progressive relaxation training
Number of subjects: 27
Study 8325826 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma self-management program (for children with low self-care practices)
Number of subjects: 27
Study 8325826 — intervention group
Group type: COMPARATOR
Intervention: Control group (initially maintained)
Number of subjects: 27
Study 3937367 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0
Study 3937367 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics
Number of subjects: 0
Study 29055814 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidomain lifestyle intervention (diet, exercise, cognition, and vascular risk management)
Number of subjects: 1260
Study 29055814 — intervention group
Group type: COMPARATOR
Intervention: Regular health advice (Control)
Number of subjects: 1260
Study 27207435 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-related activity interference
Number of subjects: 154
Study 27207435 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue-related activity interference
Number of subjects: 154
Study 24723282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftobiprole 500 mg every 8 hours
Number of subjects: 781
Study 24723282 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g every 8 hours plus linezolid 600 mg every 12 hours
Number of subjects: 781
Study 22240497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (200 mg/day) for 8 weeks
Number of subjects: 23
Study 22240497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 22240497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol (200 mg/day)
Number of subjects: 23
Study 19855311 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (half-squats, 4 sets of 4 repetitions maximum, 3 times per week for 8 weeks)
Number of subjects: 16
Study 19855311 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal endurance training)
Number of subjects: 16
Study 18241647 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqing Shuangjie Capsule (treatment group A)
Number of subjects: 360
Study 18241647 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqing Shuangjie Tablet (treatment group B)
Number of subjects: 360
Study 18241647 — intervention group
Group type: COMPARATOR
Intervention: Chaihuang Tablet and Yiqing Shuangjie Capsule analogues (control group)
Number of subjects: 360
Study 15763605 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination oxycodone 5 mg/ibuprofen 400 mg
Number of subjects: 456
Study 15763605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study 15763605 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone alone
Number of subjects: 456
Study 15763605 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen alone
Number of subjects: 456
Study 12937311 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin
Number of subjects: 50
Study 12937311 — intervention group
Group type: COMPARATOR
Intervention: 2.27% glucose
Number of subjects: 50
Study 11200017 — intervention group
Group type: EXPERIMENTAL
Intervention: gated 99Tc(m)-sestamibi (MIBI) SPECT
Number of subjects: 33
Study 9181183 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of synthetic steroids administered orally starting on day 8 of the menstrual cycle (group I)
Number of subjects: 10
Study 9181183 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of synthetic steroids administered orally starting on day 10 of the menstrual cycle (group II)
Number of subjects: 10
Study 1543034 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 31
Study 1543034 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 31
Study 3935376 — intervention group
Group type: EXPERIMENTAL
Intervention: gliclazide
Number of subjects: 96
Study 3935376 — intervention group
Group type: EXPERIMENTAL
Intervention: glibenclamide
Number of subjects: 96
Study 3935376 — intervention group
Group type: EXPERIMENTAL
Intervention: gliquidone
Number of subjects: 96
Study 28924729 — intervention group
Group type: EXPERIMENTAL
Intervention: Dor fundoplication
Number of subjects: 73
Study 28924729 — intervention group
Group type: COMPARATOR
Intervention: Toupet fundoplication
Number of subjects: 73
Study 27015382 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sleep (EXT, 9.8 ± 0.1 h time in bed)
Number of subjects: 12
Study 27015382 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (HAB, 8.2 ± 0.1 h time in bed)
Number of subjects: 12
Study 27015382 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sleep (EXT)
Number of subjects: 12
Study 27015382 — intervention group
Group type: COMPARATOR
Intervention: Habitual sleep (HAB)
Number of subjects: 12
Study 25247033 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-on-needle (HN) technique
Number of subjects: 10
Study 25247033 — intervention group
Group type: COMPARATOR
Intervention: Hand-on-syringe (HS) technique
Number of subjects: 10
Study 22194379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebral perforation
Number of subjects: 108
Study 22194379 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty (PVP)
Number of subjects: 108
Study 20482511 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 18666717 — intervention group
Group type: EXPERIMENTAL
Intervention: Manuka honey
Number of subjects: 108
Study 18666717 — intervention group
Group type: COMPARATOR
Intervention: Hydrogel
Number of subjects: 108
Study 18666717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 11704703 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (dihydropyridine calcium channel blocker)
Number of subjects: 0
Study 11704703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine monotherapy
Number of subjects: 0
Study 11704703 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 0
Study 11704703 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis based on Syst-Eur data
Number of subjects: 0
Study 9414371 — intervention group
Group type: EXPERIMENTAL
Intervention: Human factors design guidance
Number of subjects: 0
Study 8500236 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐HeFT I (prazosin, hydralazine plus isosorbide dinitrate, placebo)
Number of subjects: 1446
Study 8500236 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐HeFT II (prazosin, hydralazine plus isosorbide dinitrate, placebo, enalapril)
Number of subjects: 1446
Study 8500236 — intervention group
Group type: COMPARATOR
Intervention: Enalapril treatment group
Number of subjects: 1446
Study 8500236 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐HeFT I
Number of subjects: 1446
Study 8500236 — intervention group
Group type: EXPERIMENTAL
Intervention: V‐HeFT II
Number of subjects: 1446
Study 2830895 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 7
Study 2830895 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 7
Study 2830895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29486039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bag-Mask Ventilation (BMV)
Number of subjects: 2043
Study 29486039 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Intubation (ETI)
Number of subjects: 2043
Study 27110711 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4071
Study 25701620 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS monitoring (INVOS 5100)
Number of subjects: 43
Study 25701620 — intervention group
Group type: COMPARATOR
Intervention: No NIRS monitoring
Number of subjects: 43
Study 23700339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Number of subjects: 494
Study 23700339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei CRL 431
Number of subjects: 494
Study 23700339 — intervention group
Group type: COMPARATOR
Intervention: Regular calcium content milk (RC group)
Number of subjects: 494
Study 23700339 — intervention group
Group type: COMPARATOR
Intervention: Low-lactose milk with low calcium content (LC group)
Number of subjects: 494
Study 20519346 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg rhTSH followed by a thyroid dose of 50 Gy
Number of subjects: 90
Study 20519346 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by 100 Gy
Number of subjects: 90
Study 18580042 — intervention group
Group type: EXPERIMENTAL
Intervention: EA/BA (EmbryoAssyst and BlastAssyst containing a novel stable glutamine derivative and vitamins)
Number of subjects: 41
Study 18580042 — intervention group
Group type: COMPARATOR
Intervention: BAS (BlastAssyst system containing L‐glutamine)
Number of subjects: 41
Study 16651222 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Family physicians received a summary of clinical practice guidelines at approximately 2 weeks postinjury.
Number of subjects: 428
Study 16651222 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: Family physicians and their patients received a summary of clinical practice guidelines at approximately 2 weeks postinjury.
Number of subjects: 428
Study 16651222 — intervention group
Group type: COMPARATOR
Intervention: Control Group 1: Neither the patients nor their family physicians received any information concerning the guidelines.
Number of subjects: 428
Study 12792335 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior stabilization and fusion
Number of subjects: 52
Study 12792335 — intervention group
Group type: COMPARATOR
Intervention: Posterior stabilization and fusion
Number of subjects: 52
Study 10998833 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylcobalamin 0.5 mg orally three times a day for 6 months
Number of subjects: 152
Study 10998833 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (patient education, physical therapy, and medication)
Number of subjects: 152
Study 8634725 — intervention group
Group type: EXPERIMENTAL
Intervention: Intonation training using the Intonation Meter
Number of subjects: 2
Study 8634725 — intervention group
Group type: COMPARATOR
Intervention: Regular methods of intonation training
Number of subjects: 2
Study 1467255 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated testing attempts
Number of subjects: 0
Study 1467255 — intervention group
Group type: COMPARATOR
Intervention: Teacher factor
Number of subjects: 0
Study 1467255 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of teacher factor and testing attempts
Number of subjects: 0
Study 30794051 — intervention group
Group type: EXPERIMENTAL
Intervention: WRSS1 (3x106 CFU)
Number of subjects: 103
Study 30794051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 30794051 — intervention group
Group type: EXPERIMENTAL
Intervention: WRSS1
Number of subjects: 103
Study 28597117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone for 3 days
Number of subjects: 30
Study 28597117 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium for 3 days
Number of subjects: 30
Study 25654976 — intervention group
Group type: EXPERIMENTAL
Intervention: Peganum harmala L oil, applied 4 drops 3 times a day for 4 weeks
Number of subjects: 54
Study 25654976 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control), applied 4 drops 3 times a day for 4 weeks
Number of subjects: 54
Study 24727261 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factor treatment
Number of subjects: 1185
Study 24727261 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro re nata treatment
Number of subjects: 1185
Study 24727261 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors for sporadic vision loss
Number of subjects: 1185
Study 22385527 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum (8 mm Hg)
Number of subjects: 100
Study 22385527 — intervention group
Group type: COMPARATOR
Intervention: Standard pressure pneumoperitoneum (14 mm Hg)
Number of subjects: 100
Study 19576348 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SESs), n = 196
Number of subjects: 397
Study 19576348 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PESs), n = 201
Number of subjects: 397
Study 19576348 — intervention group
Group type: COMPARATOR
Intervention: Control group (PESs)
Number of subjects: 397
Study 18777000 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine stress cardiac magnetic resonance imaging (CMRI)
Number of subjects: 141
Study 15932376 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (INFP) 200 microg o.d.
Number of subjects: 262
Study 15932376 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (IHFP) 250 microg b.i.d.
Number of subjects: 262
Study 15932376 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of INFP and IHFP
Number of subjects: 262
Study 15932376 — intervention group
Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 262
Study 15932376 — intervention group
Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 262
Study 12870789 — intervention group
Group type: COMPARATOR
Intervention: Global Improvement Scale (GIS)
Number of subjects: 0
Study 10484014 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN 9 microg
Number of subjects: 75
Study 10484014 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN 3 microg
Number of subjects: 75
Study 10484014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 8739595 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMPC (cidofovir) at 1 mg/kg
Number of subjects: 7
Study 8739595 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMPC (cidofovir) at 3 mg/kg
Number of subjects: 7
Study 8739595 — intervention group
Group type: EXPERIMENTAL
Intervention: HPMPC (cidofovir) at 10 mg/kg
Number of subjects: 7
Study 8739595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1832916 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 0
Study 1832916 — intervention group
Group type: EXPERIMENTAL
Intervention: Josamycin
Number of subjects: 0
Study 1832916 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 6308830 — intervention group
Group type: EXPERIMENTAL
Intervention: Sultopride
Number of subjects: 94
Study 6308830 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 94
Study 30362839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 0
Study 30362839 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 0
Study 28733214 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening with algorithm B (quantifying only TG-IgA in all patients) in G2 (no restrictions on test referrals)
Number of subjects: 3818
Study 28733214 — intervention group
Group type: EXPERIMENTAL
Intervention: Opportunistic screening with algorithm B in G2
Number of subjects: 3818
Study 28733214 — intervention group
Group type: COMPARATOR
Intervention: Algorithm B in G1
Number of subjects: 3818
Study 28733214 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm B in G2
Number of subjects: 3818
Study 25738338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucograft (MG; a porcine‐derived purified collagen membrane)
Number of subjects: 32
Study 25738338 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 24197612 — intervention group
Group type: EXPERIMENTAL
Intervention: Active training toward positive stimuli (n = 20)
Number of subjects: 75
Study 24197612 — intervention group
Group type: COMPARATOR
Intervention: Placebo training (n = 22)
Number of subjects: 75
Study 24197612 — intervention group
Group type: COMPARATOR
Intervention: Nondepressive control (n = 33)
Number of subjects: 75
Study 23072617 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula supplemented with a mixture of dairy lipids and plant oils
Number of subjects: 75
Study 23072617 — intervention group
Group type: COMPARATOR
Intervention: Formula containing only plant oils
Number of subjects: 75